Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pei SN et al. – Four (4.2%) of 95 HBsAg–negative patients developed de novo HBV–related hepatitis and two died of fulminant hepatitis. Rituximab–based therapy may cause serious HBV–related complications and even death in both HBsAg–positive and HBsAg–negative patients.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address